Kuangli Bio-Tech Holdings Co., Ltd. (TPE:6431)
Taiwan · Delayed Price · Currency is TWD 19.25
-0.30 (-1.53%)
Sep 8, 2026, 1:30 PM CST
Kuangli Bio-Tech Holdings Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 363.27 | 377.03 | 381.3 | 293.37 | 342.16 | 332.63 | |
Revenue Growth | -14.57% | -1.12% | 29.97% | -14.26% | 2.86% | 282.47% |
Cost of Revenue | 273.39 | 306.62 | 312.98 | 227.07 | 273.47 | 241.7 |
Gross Profit | 89.87 | 70.41 | 68.32 | 66.3 | 68.69 | 90.94 |
Selling, General & Admin | 204.9 | 185.76 | 174.15 | 149.91 | 125.19 | 91.53 |
Research & Development | 32.2 | 33.27 | 32.25 | 30.8 | 32.27 | 11.05 |
Operating Expenses | 246.55 | 227.89 | 213.38 | 179.96 | 157.71 | 98.33 |
Operating Income | -156.68 | -157.48 | -145.06 | -113.65 | -89.03 | -7.39 |
Interest Expense | -15.3 | -13.71 | -15.87 | -14.18 | -14.3 | -8.21 |
Interest & Investment Income | 8.3 | 8.02 | 1.71 | 5.13 | 2.54 | 0.46 |
Earnings From Equity Investments | - | - | - | - | - | 10.92 |
Currency Exchange Gain (Loss) | -9.92 | -9.92 | -1.19 | 1.44 | 10.95 | -0.99 |
Other Non Operating Income (Expenses) | -0.49 | -11.57 | 2.15 | 2.58 | 5.18 | 0.35 |
EBT Excluding Unusual Items | -174.09 | -184.65 | -158.26 | -118.68 | -84.66 | -4.86 |
Impairment of Goodwill | -8.39 | -8.39 | -26.01 | -9.17 | - | - |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | - | - | 0.15 | 64.27 |
Other Unusual Items | - | - | 1.87 | 4.18 | - | - |
Pretax Income | -182.48 | -193.04 | -182.4 | -123.67 | -84.51 | 59.41 |
Income Tax Expense | 7.54 | - | -9.6 | -19.51 | -13.78 | 4.78 |
Earnings From Continuing Operations | -190.01 | -193.04 | -172.79 | -104.16 | -70.73 | 54.64 |
Earnings From Discontinued Operations | - | - | - | - | -0.62 | -18.64 |
Net Income to Company | -190.01 | -193.04 | -172.79 | -104.16 | -71.35 | 36 |
Minority Interest in Earnings | -2.99 | 0.06 | - | - | 2.63 | -10.16 |
Net Income | -193 | -192.98 | -172.79 | -104.16 | -68.72 | 25.84 |
Net Income to Common | -193 | -192.98 | -172.79 | -104.16 | -68.72 | 25.84 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 98 | 93 | 69 | 57 | 56 | 51 |
Shares Outstanding (Diluted) | 98 | 93 | 69 | 57 | 56 | 51 |
Shares Change | 21.75% | 35.63% | 19.81% | 1.50% | 11.05% | 11.25% |
EPS (Basic) | -1.97 | -2.07 | -2.52 | -1.82 | -1.22 | 0.51 |
EPS (Diluted) | -1.97 | -2.07 | -2.52 | -1.82 | -1.22 | 0.51 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -254.07 | -154.65 | -77.68 | -87.58 | -43.46 | -18.67 |
Free Cash Flow Per Share | -2.60 | -1.66 | -1.13 | -1.53 | -0.77 | -0.37 |
Gross Margin | 24.74% | 18.68% | 17.92% | 22.60% | 20.08% | 27.34% |
Operating Margin | -43.13% | -41.77% | -38.04% | -38.74% | -26.02% | -2.22% |
Profit Margin | -53.13% | -51.18% | -45.32% | -35.50% | -20.09% | 7.77% |
Free Cash Flow Margin | -69.94% | -41.02% | -20.37% | -29.85% | -12.70% | -5.61% |
EBITDA | -105.23 | -105.43 | -94.08 | -75.7 | -58.24 | 11.42 |
EBITDA Margin | -28.97% | -27.96% | -24.67% | -25.80% | -17.02% | 3.43% |
D&A For EBITDA | 51.45 | 52.05 | 50.97 | 37.96 | 30.79 | 18.81 |
EBIT | -156.68 | -157.48 | -145.06 | -113.65 | -89.03 | -7.39 |
EBIT Margin | -43.13% | -41.77% | -38.04% | -38.74% | -26.02% | -2.22% |
Effective Tax Rate | - | - | - | - | - | 8.04% |